New era for drug discovery and development in renal disease

Toshio Miyata, Katsushi Kikuchi, Hideyasu Kiyomoto, Charles Van Ypersele De Strihou

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)

Abstract

Drug discovery and development is a lengthy and expensive process. Testing new agents in humans at an early stage could reduce the time and costs involved in identifying drugs that are likely to succeed in clinical studies. New guidance has outlined the concept of exploratory clinical trials, which provide important information on a drug's distribution as well as its physiological and pharmacological effects in humans. This strategy reduces the need for preclinical testing by limiting the dose and duration of exposure to a new drug in humans to below those required by the traditional testing of investigational new drugs. Exploratory, first-in-man studies should provide insights into human physiology and pharmacology, identify therapeutic targets relevant to disease and increase our knowledge of a drug's characteristics. Implementation of a new drug also requires the development of useful biomarkers of disease and of the drug's efficacy, as well as sensitive molecular imaging techniques. In this Review, we outline the benefits of exploratory clinical trials, especially in academia, and provide an overview of the experimental tools necessary for rational drug discovery and development.

Original languageEnglish
Pages (from-to)469-477
Number of pages9
JournalNature Reviews Nephrology
Volume7
Issue number8
DOIs
Publication statusPublished - 2011 Aug

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'New era for drug discovery and development in renal disease'. Together they form a unique fingerprint.

Cite this